Silvus Appoints Aerospace and Technology Executive Eduardo Iniguez As Chief Financial Officer
In his new role at Silvus,
"Eduardo's financial leadership background in aerospace manufacturing, combined with his entrepreneurial experience in high growth technology sectors makes him uniquely qualified to help guide Silvus' financial strategy to achieve its next stage of growth," said
Before joining Silvus,
"Silvus Technologies is an amazing organization dedicated to solving the toughest tactical communication problems on the planet," said
About Silvus Technologies, Inc.
As the world's leading provider of advanced MANET and MIMO communications systems, Silvus Technologies is reshaping mesh network technology for mission-critical applications – on the ground, in the air, and at sea. Its battle proven StreamCaster family of MANET radios and proprietary MN-MIMO waveform provides the vital communications link for defense, law enforcement, and public safety agencies around the world, and in the toughest operational environments. Developed by a team of top PhD scientists and design engineers, Silvus Technologies continues to innovate communications technology for the tactical edge with unmatched range, data throughput, EW resiliency, and scalability. Silvus Technologies is privately held with world headquarters located in
Media Contact: Keith Swenson, 310.614.9897, [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/silvus-appoints-aerospace-and-technology-executive-eduardo-iniguez-as-chief-financial-officer-301994193.html
SOURCE Silvus Technologies, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rihanna's Golden Dragon Gown has arrived: Guo Pei's Garden of Ethereal Realms Exhibition Opens at China National Silk Museum
- Faraday Future Announces This Week’s Investor Weekly Report from YT Jia Has Been Rescheduled to October 14; FFR and FFAI to Host Joint New Product Launch Event on October 14
- InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share